Lineage Cell Therapeutics' Q3 net loss widens, driven by warrant liabilities

Lineage Cell Therapeutics

06/11/2025 21:12

Overview

Lineage Q3 revenue decreased to $3.7 mln from $3.8 mln in 2024

Net loss for Q3 increased to $29.75 mln, driven by warrant liabilities

Outlook

Lineage plans to drive milestone revenue from Roche and Genentech alliance

Lineage aims to capitalize on investments in cell transplant platform

Result Drivers

COLLABORATION WITH WDI - Lineage entered a collaboration with William Demant Invest to fund preclinical development of ReSonance, covering up to $12 mln in costs

MANUFACTURING CAPABILITY - Lineage completed cGMP production runs for OpRegen and OPC1, highlighting scalable production capabilities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$29.75 mln
Q3 Operating Expenses
$7.47 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lineage Cell Therapeutics Inc is $3.00, about 39.5% above its November 5 closing price of $1.82

Press Release: ID:nBw2kxXlpa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)